It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Modified Vaccinia Ankara (MVA) was recently approved as a smallpox vaccine. Variola is transmitted by respiratory droplets and MVA immunization by skin scarification (s.s.) protected mice far more effectively against lethal respiratory challenge with vaccinia virus (VACV) than any other route of delivery, and at lower doses. Comparisons of s.s. with intradermal, subcutaneous, or intramuscular routes showed that MVAOVA s.s.-generated T cells were both more abundant and transcriptionally unique. MVAOVA s.s. produced greater numbers of lung Ova-specific CD8+ TRM and was superior in protecting mice against lethal VACVOVA respiratory challenge. Nearly as many lung TRM were generated with MVAOVA s.s. immunization compared to intra-tracheal immunization with MVAOVA and both routes vaccination protected mice against lethal pulmonary challenge with VACVOVA. Strikingly, MVAOVA s.s.-generated effector T cells exhibited overlapping gene transcriptional profiles to those generated via intra-tracheal immunization. Overall, our data suggest that heterologous MVA vectors immunized via s.s. are uniquely well-suited as vaccine vectors for respiratory pathogens, which may be relevant to COVID-19. In addition, MVA delivered via s.s. could represent a more effective dose-sparing smallpox vaccine.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Brigham and Women’s Hospital, Harvard Medical School, Department of Dermatology and Harvard Skin Disease Research Center, Boston, USA
2 Brigham and Women’s Hospital, Harvard Medical School, Department of Dermatology and Harvard Skin Disease Research Center, Boston, USA; Capital Medical University, Beijing Institute of Traditional Chinese Medicine, Beijing Hospital of Traditional Chinese Medicine, Beijing, China (GRID:grid.24696.3f) (ISNI:0000 0004 0369 153X)
3 Brigham and Women’s Hospital, Harvard Medical School, Department of Dermatology and Harvard Skin Disease Research Center, Boston, USA (GRID:grid.24696.3f)
4 Harvard Medical School, Department of Biomedical Informatics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
5 Chinese Academy of Sciences, The Center for Microbes, Development and Health, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Shanghai, China (GRID:grid.9227.e) (ISNI:0000000119573309)
6 Brigham and Women’s Hospital, Harvard Medical School, Department of Dermatology and Harvard Skin Disease Research Center, Boston, USA (GRID:grid.9227.e); Dana-Farber/Brigham and Women’s Cancer Center, Boston, USA (GRID:grid.417747.6) (ISNI:0000 0004 0460 3896)